Importantly, activation of tyrosine kinases including LYN, FYN, and AXL has been reported in IM and Nilotinib-resistant cell lines and also in some CML patients treated with such inhibitors [9-11]. The gene discussed is LYN; the disease is chronic myelogenous leukemia, BCR-ABL1 positive.